Dr. Reddy’s Competition For Perrigo’s Omeprazole Delayed Six Months
This article was originally published in The Tan Sheet
Executive Summary
Private label leader Perrigo should have an additional six months without competition from Dr. Reddy's against the firm's top-selling OTC product, the proton pump inhibitor omeprazole
You may also be interested in...
Perrigo Gains 180-Day Exclusivity With ANDA Approval For Omeprazole Magnesium PPI
Perrigo receives approval for its ANDA for a Prilosec OTC equivalent and another for a generic of Advil Fast Relief. The firm includes those products in its outlook for $1 billion in new product sales over three years.
Perrigo Gains 180-Day Exclusivity With ANDA Approval For Omeprazole Magnesium PPI
Perrigo receives approval for its ANDA for a Prilosec OTC equivalent and another for a generic of Advil Fast Relief. The firm includes those products in its outlook for $1 billion in new product sales over three years.
Perrigo Plots Nutritionals Turnaround Following Record Year
Turning around a nutritionals business saddled with high costs remains a top priority for Perrigo as it reports record overall sales in its fiscal 2009